激光周边虹膜切开术与激光周边虹膜切开术联合激光周边虹膜成形术治疗多机制房角关闭:随机对照试验研究方案
中国原发性房角关闭(PAC)疾病负担居全球首位,房角关闭机制复杂。本研究为为期3年、多中心、随机、平行组、开放标签、优效性试验,拟从中国十家眼科中心招募240例经超声生物显微镜(UBM)评估确认多机制房角关闭(MAC)的PAC成人患者,随机接受单纯激光周边虹膜切开术(LPI)或LPI联合激光周边虹膜成形术(LPIP),主要结局为疾病进展率,随访3年。
要点
- 拟招募240例经UBM确认多机制房角关闭的PAC成人患者,随机分入单纯LPI组或LPI联合LPIP组。
- 主要结局为疾病进展率,采用Pearson χ2检验比较两组,并以logistic回归分析校正中心效应。
- 若LPI联合LPIP显著降低PAC进展率,该干预可能成为多机制房角关闭PAC的标准治疗。
核心结论
- 若LPI联合LPIP被证实显著降低PAC进展率,该干预可能成为多机制房角关闭PAC的标准治疗,并可能延缓PAC进展至PACG、推迟抗青光眼药物或小梁切除术的时间。
研究设计与样本
- 为期3年、多中心、随机、平行组、开放标签、优效性试验,拟从中国十家眼科中心招募240例经UBM评估确认多机制房角关闭的PAC成人患者,随机分配接受单纯LPI或LPI联合LPIP,随访3年。
主要发现
- 主要结局为疾病进展率,采用Pearson χ2检验比较LPI组与LPI联合LPIP组,并进行logistic回归分析以校正中心效应。
关键数值与推荐
- 主要结局为疾病进展率,采用Pearson χ2检验比较LPI组与LPI联合LPIP组。
- 采用logistic回归分析校正中心效应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: China has the largest burden of primary angle-closure glaucoma (PACG) worldwide. The mechanism of the angle closure is complex and includes pupillary block and non-pupillary block. Currently, opinion is that laser peripheral iridotomy (LPI) alone is not sufficient to prevent disease progression. Laser peripheral iridoplasty (LPIP) is an alternative and effective way of widening the angle recess in eyes that are affected by primary angle closure (PAC). However, it is not known if greater benefit would be achieved using LPI plus LPIP for PAC with multiple mechanisms (MAC). Thus, the aim of this study is to demonstrate if LPI plus LPIP would be more effective than single LPI in controlling the progression of PAC with multiple mechanisms, based on ultrasound biomicroscopy (UBM) classification. A secondary aim is to determine whether or not this would result in the use of less medication and/or prolong the time to antiglaucoma surgery. METHODS: This multiple-mechanism angle-closure study will comprise a 3-year, multicenter, randomized, parallel-group, open-label, superiority trial, the aim of which will be to evaluate the safety and efficacy of LPI plus LPIP versus LPI for PAC. It is anticipated that 240 adults, diagnosed with PAC (the mechanism of angle closure will be assessed by UBM and it will be determined whether or not it involves multiple mechanisms) will be recruited from ten ophthalmic centers in China. Participants will be randomly allocated to receive either single LPI or LPI plus LPIP. Participant assessment will be designed to test the rate of disease progression and who will be followed up for 3 years. The primary outcome will be the disease progression rate and a comparison will be made between the LPI and LPI plus LPIP groups using Pearson's χ2 test. Logistic regression analysis will be performed to account for the central effect. DISCUSSION: If the LPI plus LPIP is found to significantly decrease the rate of PAC progression, this intervention could potentially be a standard therapy to be used to treat PAC when multiple mechanisms are involved in angle closure. Subsequently, this would have the potential to delay the rate of PAC progression to PACG and delay the time to the administration of antiglaucoma medication or trabeculectomy surgery. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02613013 . Registered on 24 November 2015. In fact, the study was due to start in late October 2015, however, there were no patients recruited in October, and when we registered at ClinicalTrials.gov on 5 November 2015, we received suggestions on the English translation of our protocol from the PRS Team at Clinicaltrial.gov, so the final successful registration date was on 24 November 2015.
引用
- Chen S, Lv J, Fan S, et al. Laser peripheral iridotomy versus laser peripheral iridotomy plus laser peripheral iridoplasty in the treatment of multi-mechanism angle closure: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28302178. doi:10.1186/s13063-017-1860-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。